SCHEMBL6415083

SCHEMBL6415083

Oc1c(Br)cc(Br)cc1C=NNc1nc2nonc2nc1Nc1cccc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.47
KMT2A Q03164 12/20 0.47
MAPT P10636 12/20 0.47
NPC1 O15118 6/20 0.47
RAB9A P51151 4/20 0.47
POLB P06746 3/20 0.47
GAA P10253 2/20 0.47
GFER P55789 2/20 0.47
SMN1; SMN2 Q16637 7/20 0.41
TP53 P04637 2/20 0.41
MCL1 Q07820 1/20 0.41
HSPD1 P10809 1/20 0.39
HSPE1 P61604 1/20 0.39
DDX3X O00571 1/20 0.39
KDM4E B2RXH2 7/20 0.38
HPGD P15428 3/20 0.38
HK1 P19367 1/20 0.38
LMNA P02545 5/20 0.37
HTT P42858 4/20 0.37
L3MBTL1 Q9Y468 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414734 0.89 MEN1 (0.48) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL6432678 0.89 MEN1 (0.51) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL6416370 0.89 MAPT (0.41) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL6416374 0.89 MAPT (0.41) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL6416047 0.88 MAPT (0.41) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL6416048 0.88 MAPT (0.41) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL6412900 0.87 MEN1 (0.45) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL6419626 0.83 MEN1 (0.47) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL6470009 0.83 DDX3X (0.55) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL6418357 0.83 MAPT (0.47) MEN1KMT2AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MEN1 4392/4885KMT2A 3640/4885MAPT 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.